Aerie Pharmaceuticals Inc.

Aerie Pharmaceuticals — Investor Presentation (June 2020)

29 slides from Aerie Pharmaceuticals's investor presentation, Jun 17, 2020

  1. Slide 1: Company Overview Investor Presentation June 2020

    Company Overview Investor Presentation June 2020 Exhibit 99.1

  2. Slide 2: Important Information

    For Investor Use Important Information The information in this presentation does not contain all of the information that a potential investor should review before investing in Aerie shares. The descriptions of Aerie Pharmaceuticals, Inc. (the “Company” or “Aerie”) in this presentation are qualified

  3. Slide 3: Aerie Overview

    Aerie Overview Rhopressa® has not been approved by any regulatory authorities other than the FDA and EMA and Rocklatan® has not been approved by any regulatory authority other than the FDA. Additional potential Rhopressa® indications are being considered for further study and are not labeled indicat

  4. Slide 4: Aerie Overview: Glaucoma Market

    Aerie Overview For Investor Use Sources: IQVIA: NPA Rx and NSP Unit data Graph Source: IQVIA 2019 CAI: Carbonic Anhydrase Inhibitor AA: Alpha Agonist BB: Beta Blocker Estimated Glaucoma Market TRx Mix - ~$3B Market, 36M TRx, 55M bottles - 55% of unit volume first-line (PGAs) - 45% of unit volume 2-3

  5. Slide 5: Rocklatan Phase 3 Month 12 Responder Analysis

    For Investor Use Rocklatan® Phase 3 Month 12 Responder Analysis: Goal is to Achieve Lowest IOP Possible At Month 12: % of Patients with IOP Reduced to 18 mmHg or Lower *p<0.05, **p<0.01, ***p<0.0001 ++Data on File Based on Mercury 1 Interim Analysis 2 Rocklatan® has not been approved by any regulato

  6. Slide 6: Topline Results from Rhopressa Phase 4 MOST Study

    Topline Results from Rhopressa® Phase 4 Multi-center Open-label Study (MOST) 12-week MOST study evaluated efficacy, tolerability and safety of Rhopressa® use in 260 patients in a real-world clinical setting Use of Rhopressa® as monotherapy or adjunct was at discretion of the physician Used adjunctiv

  7. Slide 7: U.S. Glaucoma Franchise Launch Update

    For Investor Use U.S. Glaucoma Franchise Launch Update Rhopressa® has not been approved by any regulatory authorities other than the FDA and EMA and Rocklatan® has not been approved by any regulatory authority other than the FDA. Actual Weekly Sales-Out to Pharmacies Data as of 6/12/2020 IQVIA Weekl

  8. Slide 8: U.S. Glaucoma Franchise: TRx/NRx % Change versus prior week

    U.S. Glaucoma Franchise: TRx/NRx % Change versus prior week For Investor Use Source: IQVIA Rhopressa® bottles per Rx year-to-date 2020 were 1.38 compared to same period 2019 of 1.27, reflecting an increase in 90 days’ supply. The decline of TRx’s, and particularly NRx’s, from late March into April 2

  9. Slide 9: IQVIA Prescription Data

    IQVIA Prescription Data Refill prescriptions holding flat. New/Renewal prescriptions have improved. For Investor Use

  10. Slide 10: TRx Growth By Branded Product

    TRx Growth By Branded Product For Investor Use Source: IQVIA Product Q1 ‘20 TRx Change from Q1 ‘19 ↓ Aerie Franchise 137,854 66,084 Vyzulta® 41,481 16,448 Combigan® 452,798 10,766 Lumigan® 572,719 9,931 Zioptan® 33,615 1,302 Simbrinza® 117,666 -8,138 Cosopt Pf® 14,043 -9,163 Alphagan® P 231,489 -14,

  11. Slide 11: Market Access as of June 2020

    For Investor Use Market Access as of June 2020 Rhopressa® Commercial ~ 90% of covered lives Medicare Part D ~ 88% of covered lives Rocklatan® Commercial ~ 88% of covered lives Medicare Part D ~ 55% of covered lives An additional 15% of remaining Medicare Part D lives have affordable access through U

  12. Slide 12: Aerie & COVID-19: U.S. Sales Activities

    Aerie & COVID-19: U.S. Sales Activities Sales: Utilizing a new sales tool kit with a digital focus Sales reps communicating with physicians using virtual detailing platforms (such as Zoom) and email Weekly email blasts and increasing video content Webinars for physicians (replacing local speaker mee

  13. Slide 13: 84% of OPH offices currently open

    84% of OPH offices are currently open while a variety of mechanisms are being deployed For Investor Use Source: Market Research

  14. Slide 14: Aerie & COVID-19: Ex-U.S. Activities & Pipeline

    Aerie & COVID-19: Ex-U.S. Activities & Pipeline Ex-U.S. Activities Europe: Mercury 3 readout potentially by late 2020 Japan: PMDA meeting completed in April 2020 Pipeline AR-1105: Enrollment complete; readout for H2 20 remains on track AR-13503: Minimum enrollment complete, study remains on track to

  15. Slide 15: Expanding Aerie Franchise: Europe

    For Investor Use Expanding Aerie Franchise: Europe Marketing authorisation granted for Rhokiinsa® (Rhopressa®) in November 2019; Roclanda® (Rocklatan®) MAA accepted for review in December 2019 Mercury 3: 6-month safety and 90-day efficacy registration trial comparing Rocklatan® (known as Roclanda® i

  16. Slide 16: Expanding Aerie Franchise: Japan

    For Investor Use Expanding Aerie Franchise: Japan Phase 2 study successful top-line results released in November 2019 Phase 3 trials expected to be conducted in Japan Sources: IMS Analytics link at ex-manufacturer price level and Unit-April 2020. *TRx calculated from IQVIA unit data (1 month = 1 TRx

  17. Slide 17: Japan Phase 2 Study Topline Results

    AR-13324-CS208 Japan Phase 2 Study Topline Results 28-day prospective, double-masked, placebo-controlled, dose-ranging study of netarsudil efficacy and safety in Japanese subjects with open-angle glaucoma (OAG) or ocular hypertension (OHT) Netarsudil 0.01%, 0.02% and 0.04% were efficacious, met prim

  18. Slide 18: Advancing the Pipeline

    For Investor Use Advancing the Pipeline Drug/Target Indication Development Stage Preclinical Phase 1/2a Phase 2b Front of the Eye AR-15512 (AVX TRPM8 agonist) Dry Eye Back of the Eye AR-1105 Implant (Dexamethasone) RVO/DME AR-13503 Implant (ROCK, PKC) wAMD DME/DR Glaucoma Neuro- enhancement

  19. Slide 19: U.S. Dry Eye Market

    For Investor Use U.S. Dry Eye Market Estimated 30 million dry eye sufferers in the United States Less than 3 million treated Sources: Mixture of public information, IQVIA , Market Scope and estimates – Feb 2020 US 2019 Sales: $1.6B est.

  20. Slide 20: AVX-012 (now named AR-15512) for Dry Eye

    For Investor Use AVX-012 (now named AR-15512) for Dry Eye Novel Mechanism of Action – Modulation of Corneal TRPM8 receptors TRPM8 receptor is a cold thermoreceptor involved in basal tear production (i.e.; sign) Modulation of TRPM8 also provides a cooling sensation upon instillation (i.e.; symptom) T

  21. Slide 21: AR-15512 (TRPM8 Agonist) for Dry Eye

    AR-15512 (TRPM8 Agonist) for Dry Eye For Investor Use How AR-15512 works AR-15512 Ophthalmic Solution

  22. Slide 22: AVX-012 (AR-15512) Dry Eye Clinical Trial Highlights

    AVX-012 (AR-15512) Dry Eye Clinical Trial Highlights Significant efficacy achieved for sign and symptoms with BID dosing of 0.0014% (50µM) AVX-012 (AR-15512) over 28 days Sign: Schirmer Evaluation Percentage of patients improving ≥3mm Symptoms: SANDE Score Percentage of patients improving ≥20 score

  23. Slide 23: Bringing Small Molecule Therapy to Back of the Eye

    Bringing Small Molecule Therapy to Back of the Eye Most retinal drugs in use and in pipeline are protein therapeutics Longer half-life allows monthly to bimonthly IVT injections Protein therapeutics address limited number of extracellular targets Small molecules address a wider array of therapeutic

  24. Slide 24: Aerie's Ophthalmic Implant Platform

    For Investor Use Aerie’s Ophthalmic Implant Platform Small Molecule Drug Candidates Proprietary Drug Delivery Technology Bio-erodible, sustained-release implant for intravitreal injection DSM PEA Polymer PLGA PRINT® Mfg AMD DME RVO Dry AMD/GA Glaucoma Others Aerie Kinase Library Non-Aerie drug candi

  25. Slide 25: 2019 U.S. Retinal Disease Market

    For Investor Use 2019 U.S. Retinal Disease Market Sources: Mixture of public information, IQVIA, Market-Scope and estimates – Feb 2020 2019 Sales: $6.8B 2019 Unit Sales: 8.1MM

  26. Slide 26: Aerie's Sustained Implant Opportunities

    For Investor Use Aerie’s Sustained Implant Opportunities Markets in Need of Further Innovation: Retinal Vein Occlusion (RVO) Wet Age Related Macular Edema (wAMD) Diabetic Macular Edema (DME) Broadly Underserved Market Opportunities: Glaucoma Neuro-enhancement Dry AMD/Geographic Atrophy (GA)

  27. Slide 27: Aerie's Lead Implant Product Candidates

    For Investor Use Aerie’s Lead Implant Product Candidates AR-1105 (Dexamethasone) Implant (Phase 2 readout ~ H2 2020) Indications under development: retinal vein occlusion (RVO) Target product profile vs. Ozurdex® Designed for longer duration of efficacy (6 mo vs 3 mo) Designed for improved administr

  28. Slide 28: Aerie's Key Catalysts for 2020

    Aerie’s Key Catalysts for 2020 Pipeline: Avizorex TRPM8 agonist for Dry Eye Phase 2/3 clinical study expected to commence H2 2020 AR-1105 Phase 2 RVO clinical study readout expected H2 2020 AR-13503 stage 2 clinical study expected to commence H2 2020 Globalization: Roclanda® Mercury 3 topline readou

  29. Slide 29: Summary: Key Priorities

    For Investor Use Summary Key Priorities Successful commercialization in U.S. of Rhopressa® and Rocklatan® Globalization Strategy Europe/Japan clinical path and commercialization strategy Ireland Manufacturing Facility Research Initiatives Avizorex TRPM8 agonist for dry eye Retina Program Well-Financ

Aerie Pharmaceuticals — Investor Presentation (June 2020) on 6ix